Kaleido Biosciences, Inc. Common Stock
KLDO
KLDO was delisted on the 14th of April, 2022.
61 hedge funds and large institutions have $273M invested in Kaleido Biosciences, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 16 increasing their positions, 9 reducing their positions, and 8 closing their positions.
78% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 9
63% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 8
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
9% more funds holding
Funds holding: 56 → 61 (+5)
15% less capital invested
Capital invested by funds: $320M → $273M (-$47.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.44M |
| 2 |
BlackRock
New York
|
+$3.32M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$844K |
| 4 |
Millennium Management
New York
|
+$356K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$314K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HP
Harbourvest Partners
Boston,
Massachusetts
|
-$707K |
| 2 |
MAM
Martingale Asset Management
Boston,
Massachusetts
|
-$345K |
| 3 |
Squarepoint
New York
|
-$267K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$223K |
| 5 |
Two Sigma Investments
New York
|
-$144K |
KLDO Hedge Fund Activity: Q4 2020 in Review
61 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Kaleido Biosciences, Inc. Common Stock (KLDO) for Q4 2020, worth a combined $273M — down 15% from $320M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new KLDO positions and 8 closed out — a net gain of 5 holders — while 16 added to existing stakes and 9 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $4.44M. The largest seller was Harbourvest Partners, cutting an estimated $707K.
- 61 institutional investors held Kaleido Biosciences, Inc. Common Stock (KLDO) as of Q4 2020, up from 56 in Q3 2020.
- Funds reported $273M of Kaleido Biosciences, Inc. Common Stock stock for Q4 2020, down 15% quarter-over-quarter.
- 13 funds opened new Kaleido Biosciences, Inc. Common Stock positions in Q4 2020 and 8 closed out, a net change of +5 holders.
- The largest Kaleido Biosciences, Inc. Common Stock buyer in Q4 2020 was Fidelity Investments, an estimated $4.44M added.
- The largest Kaleido Biosciences, Inc. Common Stock seller in Q4 2020 was Harbourvest Partners, an estimated $707K sold.
Based on aggregated 13F filings for Q4 2020.